SABS · SAB Biotherapeutics, Inc.
$3.45
+0.01 (+0.29%)
At close · Jul 28
Market Cap
$263.04M
Shares
76.46M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.45
Open$3.40
Day$3.35–3.49
52W$1.85–5.15
Avg vol 30d990K
Short int4.4M · 5.7% float · 9.4d
Short vol70%
DataFeb 2021–Jul 2026
Filing10-Q · May 12
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
Death cross
Price vs 200-day avg
−7%
below
Price vs 50-day avg
−6%
below
RSI (14)
40
neutral
MACD trend
Negative
52-week position
48%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−9%
trailing
6-month return
−21%
trailing
YTD return
−8%
this year
Relative strength
−29%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
Death cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow
Distributing
4 of 79 funds reported for Jun 30 · net -30.9K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.72% of float · ▲ +16.0% MoM · 9.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
79 holders — near 2-yr high, broad support
Squeeze score
77
high risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+79%
Y/Y
Free cash flow
$-45.7M
Balance sheet
$10.5M
net cash
Quant / Vol
risk profile
Volatility
77%
annualized · 1-yr
Max drawdown
−30%
past year
ATR
5.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
Death cross
Bearish
Price vs 200-day avg
−7%
Bearish
Price vs 50-day avg
−6%
Bearish
RSI (14)
40
Neutral
MACD trend
Negative
Bearish
52-week position
48%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
Death cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow
Distributing
4 of 79 funds reported for Jun 30 · net -30.9K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.72% of float · ▲ +16.0% MoM · 9.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
79 holders — near 2-yr high, broad support
Price context
position in its 52-week range
52-wk low $2
Now $3 · 48%
52-wk high $5
vs 200-day avg -7%
vs 50-day avg -6%
50-day below 200-day death cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SABS
this stock
SAB Biotherapeutics, Inc.
|
$263.04M | -7.8% | -100.0% | — | 5.7% |
|
ONC
BeOne Medicines Ltd.
|
$471.01B | +7.3% | +22179.2% | 958.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.57B | +8.2% | +46.2% | 28.4 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.95B | -9.8% | +20.8% | 16.3 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SABS | -1.7% | -9.2% | -21.2% | -11.5% | -7.8% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -0.7% | -9.2% | -28.7% | -10.8% | -16.4% |